Dockery LE, Rubenstein AR, Ding K, et al. - In this multi-institutional retrospective review, researchers investigated the influence of administering non-platinum or targeted therapy in 2nd line in epithelial ovarian cancer (EOC) patients recurring 6–12 months following completion of primary platinum-based chemotherapy. They analyzed 177 patients with recurrent EOC and platinum-free interval (PFI) of 6–12 months after primary chemotherapy. For 2nd line treatment in these patients, they compared platinum vs non-platinum chemotherapy or targeted therapy. Overall 177 patients were included, of these, most were Caucasian, exhibited serous histology, and had received primary cytoreductive surgery. In 28% of patients, second line platinum was omitted. Findings revealed worse survival in relation to the use of non-platinum chemotherapy and even targeted therapy to prolong PFI in patients with EOC recurring between 6 and 12 months.